Sandhya Girish

Gilead Sciences (United States) — United States

Medicine · Health Sciences

33h-index5.4kcitations140works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(81), Monoclonal and Polyclonal Antibodies Research(69), Cancer Treatment and Pharmacology(19), Cancer Immunotherapy and Biomarkers(18), Peptidase Inhibition and Analysis(17)

Publications140 total

Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using <scp>HR</scp>+/<scp>HER2</scp>− Metastatic Breast Cancer Data From the Phase 3 <scp>TROPiCS</scp>‐02 Trial
Clinical and Translational Science·2025Open Access
Gen AI Driven FAQ Chatbot Using Advanced RAG Architecture for Querying Annual Reports
2025
Modeling the Interplay Between Viral and Immune Dynamics in <scp>HIV</scp>: A Review and Mrgsolve Implementation and Exploration
Clinical and Translational Science·2025· 1 citedOpen Access
Effect of Food Intake or Coadministration With an Acid‐Reducing Agent on Lenacapavir Pharmacokinetics Following Oral Administration
Clinical Pharmacology in Drug Development·2025· 1 cited
Exposure–Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple‐Negative Breast Cancer
Clinical Pharmacology & Therapeutics·2024· 12 citedOpen Access
OP16.08: Perinatal outcomes of monochorionic diamniotic twin pregnancies complicated by selective fetal growth restriction in a selected tertiary fetal care centre
Ultrasound in Obstetrics and Gynecology·2024Open Access
Fused filament fabrication of Stainless Steel 316L: Investigation on effect of printing parameters on microstructural and mechanical strength of sintered part
International Journal of Scientific and Research Publications·2024· 1 cited
Impact of COVID‒19 Pandemic on Clinical Pharmacology Trials in Japanese Subjects Conducted at Phase 1 Units in Japan or Overseas
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics·2024
Abstract PO1-04-06: Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic breast cancer
Cancer Research·2024· 1 cited
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
Clinical Pharmacokinetics·2024· 15 citedOpen Access
Impact of <scp>COVID</scp>‐19 on the Conduct and Design of Clinical Trials: <scp>IQ</scp> Consortium Perspective
Clinical Pharmacology & Therapeutics·2024Open Access
Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment
Antimicrobial Agents and Chemotherapy·2024· 15 citedOpen Access
Consumption pattern of different categories of rural households in Southern Karnataka
International Journal of Agriculture Extension and Social Development·2024Open Access
Model-based Meta-Analysis (MBMA) to Inform Immuotherapy (IO) Treatment Decisions in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
2024Open Access
539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for Obeldesivir
Open Forum Infectious Diseases·2023· 3 citedOpen Access
A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV
AIDS·2023· 33 citedOpen Access
801 Risk-benefit ratio in immunotherapy (IO) with or without chemotherapy (CT) according to PD-L1 expression: a model-based approach to inform treatment decisions in metastatic non-small cell lung cancer
Regular and Young Investigator Award Abstracts·2023Open Access
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
Clinical and Translational Science·2023· 8 citedOpen Access
Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: a clinical pharmacology perspective
Expert Review of Clinical Pharmacology·2023· 3 citedOpen Access
How comparable are outcomes for approved PD-1/PD-L1 checkpoint inhibitors (CPI)? A model-informed drug development approach to answer the question.
Journal of Clinical Oncology·2023
page 1 of 7Next →

Frequent Co-authors

Chunze Li(13), Amita Joshi(11), Dan Lu(10), Jin Y. Jin(10), Priya Agarwal(9), Ian E. Krop(8), Jay Tibbitts(8), Ola M. Saad(8), Howard A. Burris(7), Shanu Modi(7), Dan Lü(7), Manish Gupta(6), Ben‐Quan Shen(6), René Bruno(6), Divya Samineni(6), Dale Miles(6), Scott N. Holden(5), Joo‐Hee Yi(5), Patricia LoRusso(5), Yu‐Waye Chu(5)